We focus on developing pioneering and novel peptide Bio-drugs in specialist therapeutic areas
ImmuPharma PLC is an AIM listed (LSE:IMM) evolving speciality pharma company headquartered in London with its research team, ImmuPharma Biotech, based in Bordeaux, France
Our research strategy has been to work closely with the largest fundamental research organisation in Europe, the Centre National de la Recherche Scientifique, (CNRS) in France. This collaboration enables us to access innovative research with substantial embedded value and to work with many leading scientists and clinicians. ImmuPharma has exclusive rights to all its intellectual property assets.
Since a major Board and management restructuring, the team has refocused it key pipeline portfolio to maximise long-term shareholder value.
Our pipeline
The pipeline of innovative peptide-based therapies is focused on two core therapy areas: Autoimmunity & Inflammation and Anti-infection.
These include:
- Lupuzor™ (P140) for Lupus (Ph 2/3 adaptive/pivotal)
- P140 for CIDP (Ph 2/3 adaptive/pivotal)
- BioAMB, a novel, improved amphotericin-B (late preclinical)
- BioCIN, a novel, improved vancomycin (early preclinical)
Business development
Our commercial strategy is to out-license our assets in development at value inflection points, to leading international corporations that are well-placed to further develop and/or commercialise our drugs.
ImmuPharma and Avion Pharmaceuticals now have an exclusive licence and development agreement for Lupuzor™, where Avion Pharmaceuticals is funding a new international Phase 3 trial and commercialise in the US.
Why Invest in ImmuPharma?
- A rich portfolio with 2 highly attractive late-stage clinical indications – Lupus & CIDP
- Near-term business development opportunities across all programs
- Innovative Bio-drug platform of P140 has potential in several autoimmune diseases
The story so far...
2006
Successful listing on AIM of the London Stock Exchange
To fund the development of its lead drug candidate, Lupuzor™ through Phase 1/2 development
2008
Option agreement signed with US Cephalon Inc., for LupuzorTM
Initial US$15m upfront payment in advance to Phase 2b data being announced
2009
Positive Phase 2b results announced for LupuzorTM
• LupuzorTM successfully licensed to Cephalon
• ImmuPharma receives a further upfront payment of US$30 million from Cephalon
• US$500 million cash milestone payment structure plus high royalties on future sales
• Largest deal in Europe that year
2011
ImmuPharma regained all product rights back for LupuzorTM & P140 platform
Following the acquisition of Cephalon by Teva Pharmaceuticals
2016
A pivotal Phase 3 international study commences for LupuzorTM in lupus patients
In sites across Europe, Mauritius and USA
SPA and Fastrack designation granted by FDA
2018
Lupuzor Phase 3 trial results demonstrated a superior response rate over placebo in primary analysis
Due to a high response rate in the placebo group, this superior response did not allow statistical significance to be reached (p = 0.2631) and the trial’s primary end point was not met
2019
ImmuPharma successfully signs exclusive licence & development agreement for LupuzorTM, with US Avion Pharmaceuticals
Avion to fund new international Phase 3 trial for LupuzorTM and commercialise in the US
Avion have rights to explore clinical development for other auto-immune indications within US
2020
A new Phase 3 clinical trial design for Lupuzor™ agreed and submitted to FDA
Trial design to select the most responsive lupus patients by biomarker profile
2021
FDA agrees new optimised Phase 3 trial design
FDA requests Phase 1 PK study to assess presence of Lupuzor™ in blood after single administration
Successful Board and management team restructuring completed
Bordeaux R&D team established
Pipeline refocused on two key therapeutic areas:
• Autoimmunity & Inflammation (Lupuzor™/P140)
• Anti-infectives (BioAMB & BioCIN)
2022
MHRA approves commencement of the PK Phase I study
• Dosing commencing in February 2022
• Study results to be available around the end of Q1 2022
• Successful completion of PK study
• Ongoing discussions with FDA regarding clinical programme of Lupuzor
2023
Portfolio in two core therapy areas with 4 key assets:
Autoimmunity & Inflammation
• Lupuzor™ (P140) for Lupus (Ph 2/3 adaptive/pivotal) to commence H2 – 2023
• P140 for CIDP (Ph2/3 adaptive/pivotal)
Anti-infectives
• BioAMB, a novel, improved amphotericin-B (Late preclinical)
• BioCIN, a novel, improved vancomycin (Early preclinical)